Cargando…

Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD(+) Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells

SIMPLE SUMMARY: Multiple myeloma is a hematological malignancy of antibody-producing plasma cells in the bone marrow. Nucleotides released from cells in the tumor microenvironment act as inflammatory danger signals. CD38 and other enzymes on the surface of cancer cells hydrolyze these nucleotides to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baum, Natalie, Fliegert, Ralf, Bauche, Andreas, Hambach, Julia, Menzel, Stephan, Haag, Friedrich, Bannas, Peter, Koch-Nolte, Friedrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795599/ https://www.ncbi.nlm.nih.gov/pubmed/33396591 http://dx.doi.org/10.3390/cancers13010076

Ejemplares similares

Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells
por: Baum, Natalie, et al.
Publicado: (2021)

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
por: Pape, Luca Julius, et al.
Publicado: (2022)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
por: Bannas, Peter, et al.
Publicado: (2017)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
por: Hambach, Julia, et al.
Publicado: (2020)

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
por: Hambach, Julia, et al.
Publicado: (2022)

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
por: Schriewer, Levin, et al.
Publicado: (2020)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity
por: Menzel, Stephan, et al.
Publicado: (2018)

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
por: Schütze, Kerstin, et al.
Publicado: (2018)

cADPR Does Not Activate TRPM2
por: Riekehr, Winnie Maria, et al.
Publicado: (2022)

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
por: Bannas, Peter, et al.
Publicado: (2018)

Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque
por: Ferrero, Enza, et al.
Publicado: (2004)

Extracellular NAD and ATP: Partners in immune cell modulation
por: Haag, Friedrich, et al.
Publicado: (2007)

Apprehending the NAD(+)–ADPr-Dependent Systems in the Virus World
por: Iyer, Lakshminarayan M., et al.
Publicado: (2022)

Identification of NAD-RNA species and ADPR-RNA decapping in Archaea
por: Gomes-Filho, José Vicente, et al.
Publicado: (2023)

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
por: Bannas, Peter, et al.
Publicado: (2015)

A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation
por: Eden, Thomas, et al.
Publicado: (2018)

Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors
por: Eichhoff, Anna Marei, et al.
Publicado: (2019)

Selective inhibitors of cardiac ADPR cyclase as novel anti-arrhythmic compounds
por: Kannt, Aimo, et al.
Publicado: (2012)

T Cells of Different Developmental Stages Differ in Sensitivity to Apoptosis Induced by Extracellular NAD
por: Haag, Friedrich, et al.
Publicado: (2002)

Immuno-targeting the multifunctional CD38 using nanobody
por: Li, Ting, et al.
Publicado: (2016)

Does Cyclic ADP-Ribose (cADPR) Activate the Non-selective Cation Channel TRPM2?
por: Fliegert, Ralf, et al.
Publicado: (2020)

Selective targeting of CD38 hydrolase and cyclase activity as an approach to immunostimulation
por: Benton, Thomas Z., et al.
Publicado: (2021)

Synthesis of phosphonoacetate analogues of the second messenger adenosine 5′-diphosphate ribose (ADPR)
por: Baszczyňski, Ondřej, et al.
Publicado: (2020)

Nanobodies: new avenue to treat kidney disease
por: Wanner, Nicola, et al.
Publicado: (2021)

Nanobodies as modulators of inflammation: potential applications for acute brain injury
por: Rissiek, Björn, et al.
Publicado: (2014)

Activation of the P2X7 ion channel by soluble and covalently bound ligands
por: Schwarz, Nicole, et al.
Publicado: (2009)

P859: ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS
por: Meseguer Martinez, E., et al.
Publicado: (2022)

Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs
por: Pinto-Espinoza, Carolina, et al.
Publicado: (2022)

Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT
por: Unger, Mandy, et al.
Publicado: (2015)

CD38/cADPR Signaling Pathway in Airway Disease: Regulatory Mechanisms
por: Deshpande, Deepak A., et al.
Publicado: (2018)

Structural Basis for Enzymatic Evolution from a Dedicated ADP-ribosyl Cyclase to a Multifunctional NAD Hydrolase
por: Liu, Qun, et al.
Publicado: (2009)

Extracellular NAD(+) shapes the Foxp3(+) regulatory T cell compartment through the ART2–P2X7 pathway
por: Hubert, Sandra, et al.
Publicado: (2010)

Alternative Splicing of the N-Terminal Cytosolic and Transmembrane Domains of P2X7 Controls Gating of the Ion Channel by ADP-Ribosylation
por: Schwarz, Nicole, et al.
Publicado: (2012)

Astrocytes and Microglia Are Resistant to NAD(+)-Mediated Cell Death Along the ARTC2/P2X7 Axis
por: Rissiek, Björn, et al.
Publicado: (2020)

A simple, sensitive, and low‐cost FACS assay for detecting antibodies against the native SARS‐CoV‐2 spike protein
por: Hambach, Julia, et al.
Publicado: (2021)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano)
por: Demeules, Mélanie, et al.
Publicado: (2020)

Tuning IL-2 signaling by ADP-ribosylation of CD25
por: Teege, Sophie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6f7kipicko81an14h0gksea40e